Anti-tau antibodies and methods of use

Abstract

The invention provides anti-Tau antibodies and methods of using the same.

What is claimed is: 
     
         1 . An isolated antibody that binds human Tau, wherein the antibody comprises:
 a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 192; HVR-H2 comprising the amino acid sequence of SEQ ID NO: 193; HVR-H3 comprising the amino acid sequence of SEQ ID NO: 194; HVR-L1 comprising the amino acid sequence of SEQ ID NO: 195; HVR-L2 comprising the amino acid sequence of SEQ ID NO: 196; and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 197.   
     
     
         2 . The isolated antibody of to  claim 1 , wherein the antibody comprises: a) a heavy chain variable region (VH) comprising a sequence that is at least 95% identical to SEQ ID NO: 190; b) a light chain variable region (VL) comprising a sequence that is at least 95% identical to SEQ ID NO: 191; or c) a VH as in (a) and a VL as in (b). 
     
     
         3 . The isolated antibody of  claim 1 , wherein the antibody comprises: a) a heavy chain variable region (VH) comprising the sequence of SEQ ID NO: 190; b) a light chain variable region (VL) comprising the sequence of SEQ ID NO: 191; or c) a VH as in (a) and a VL as in (b). 
     
     
         4 . The isolated antibody of  claim 1 , wherein the antibody is an IgG1 or an IgG4 antibody. 
     
     
         5 . The isolated antibody of  claim 4 , wherein the antibody is an IgG4 antibody. 
     
     
         6 . The isolated antibody of  claim 5 , wherein the antibody comprises M252Y, S254T, and T256E mutations. 
     
     
         7 . The isolated antibody of  claim 5 , wherein the antibody comprises an S228P mutation. 
     
     
         8 . The isolated antibody of  claim 1 , wherein the antibody binds each of monomeric Tau, phosphorylated Tau, non-phosphorylated Tau, and oligomeric Tau with a KD of less than 100 nM. 
     
     
         9 . An isolated nucleic acid that encodes the antibody of  claim 1 . 
     
     
         10 . An isolated host cell comprising the nucleic acid of  claim 9 . 
     
     
         11 . A method of producing an antibody comprising culturing the host cell of  claim 10  under conditions suitable for producing the antibody. 
     
     
         12 . An immunoconjugate comprising the antibody of  claim 1  and a second therapeutic agent. 
     
     
         13 . A labeled antibody comprising the antibody of  claim 1  and a detectable label. 
     
     
         14 . A pharmaceutical composition comprising the isolated antibody of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         15 . The isolated antibody of  claim 1 , which is a monoclonal antibody. 
     
     
         16 . The isolated antibody of  claim 1 , which is a humanized or chimeric antibody. 
     
     
         17 . The isolated antibody of  claim 1 , which is an antibody fragment that binds human Tau.